Muscular dystrophy

4 trials MedDRA PT
4 Registered trials
0 Recruiting
3 Unique sponsors
5 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
M Musculoskeletal (ATC M) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
mTOR inhibitor 1 substance
Phase III: 1 Phase II: 1 Phase I (First in Human): 2

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • ML Bio Solutions Inc. Commercial
    RIBITOL
    2023-503379-33-01 5 countries 2024 n=35 Orphan
    Ended

Phase II

1 trial
  • Edgewise Therapeutics Inc. Commercial
    EDG-5506
    2022-500215-39-00 1 country 2022 n=21
    Ended

Phase I (First in Human)

2 trials
  • Atamyo Therapeutics Commercial
    ADENO-ASSOCIATED VIRUS SEROTYPE 8 EXPRESSING THE HUMAN GAMMA-SARCOGLYCAN GENE; SIROLIMUS
    2023-506440-16-00 2 countries n=5 Orphan
    Pending
  • Atamyo Therapeutics Commercial
    ADENO-ASSOCIATED VIRUS SEROTYPE 9 EXPRESSING THE HUMAN FUKUTIN RELATED PROTEIN AND TARGET SEQUENCE OF THE MIR-208A
    2023-506677-36-00 2 countries 2022 n=20 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Atamyo Therapeutics Commercial 2 Phase I (First in Human) 0
Edgewise Therapeutics Inc. Commercial 1 Phase II 0
ML Bio Solutions Inc. Commercial 1 Phase III 0
New trials by year
2022
2
2024
1
← All indication landscapes